A individual gets a dose of the Oxford/AstraZeneca coronavirus ailment vaccine at the Cacovid isolation centre, Mainland, Infectious illness medical center, Yaba, in Lagos, Nigeria.
Majority Entire world | Universal Visuals Group | Getty Photos
Biotech startup Vaccitech, which owns the know-how driving the Covid-19 vaccine designed by Oxford University and AstraZeneca, filed for a U.S. original community presenting on Friday.
The British company strategies to listing the American depositary shares on the Nasdaq beneath the image “VACC.”
Vaccitech’s earnings dropped about 30% to $4.8 million in the yr ended Dec. 31, even as its web reduction narrowed to $17.9 million from $22.7 million due to lessen study and progress costs.
The enterprise pointed out in a filing that based mostly on its knowing, it would not be entitled to get any royalties or payments from sub-licensees from the commercialization of the AstraZeneca vaccine till soon after the pandemic is around.
Vaccitech’s desire for a U.S. listing to one particular in the Uk could further undermine London’s makes an attempt to turn into a major money hub, especially immediately after Brexit.
The organization is co-established by Sarah Gilbert, professor of vaccinology at Oxford College, who led AstraZeneca’s COVID-19 vaccine improvement initiatives.
Morgan Stanley, Jefferies and Barclays are among the the offering’s underwriters.
More Stories
Key Features Every Successful Franchise Website Design Should Include
Navigating Business Insurance and Crop Insurance in North Dakota
Exploring the Potential of a Sandwich Shop Franchise Opportunity for Aspiring Entrepreneurs